Literature DB >> 16302733

Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions.

Motomu Kuroki1, Hiromi Yamada, Hirotomo Shibaguchi, Ken Hachimine, Yumiko Hirose, Tetsushi Kinugasa, Isao Ishida, Masahide Kuroki.   

Abstract

For antibody-based therapy of cancer, monoclonal antibodies (mAbs) of human origin are superior to mouse, mouse/human chimeric or humanized mAbs, because of their minimum immunogenicity to humans and their efficient collaboration with human effector cells. In the present study, human mAbs were prepared against a pancarcinoma antigen, MK-1 (Ep-CAM), using a genetically-engineered mouse (KM mouse) that contains the human immunoglobulin genes. Spleen cells from KM mice, immunized with recombinant MK-1, were fused with P3-U1 mouse myeloma cells. Of 44 anti-MK-1 clones analyzed, two were of IgG4 and the others of IgM clones. Although the two IgG4 clones were suggested to recognize the same antigenic determinant or two closely located determinants, their VK regions were encoded by different light-chain genes while their VH sequences were identical. The two IgG4 and one of the IgM clones tested revealed antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, respectively, against MK-1-expressing cells in vitro, suggesting that these fully human mAbs produced against MK-1 and their V-region genes, which are applicable for the preparation of engineered antibody fragments that may be useful for antibody-based therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302733

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM.

Authors:  Naoto Shirasu; Hiromi Yamada; Hirotomo Shibaguchi; Motomu Kuroki; Masahide Kuroki
Journal:  J Biomed Biotechnol       Date:  2012-04-03

2.  A novel IgM-H-ficolin complement pathway to attack allogenic cancer cells in vitro.

Authors:  Xiaoying Lei; Chaoxu Liu; Kazem Azadzoi; Cuiling Li; Fan Lu; An Xiang; Jianbin Sun; Yanhai Guo; Qingchuan Zhao; Zhen Yan; Jinghua Yang
Journal:  Sci Rep       Date:  2015-01-16       Impact factor: 4.379

Review 3.  Human monoclonal antibodies from transgenic mice.

Authors:  N Lonberg
Journal:  Handb Exp Pharmacol       Date:  2008

4.  Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.

Authors:  Naoto Shirasu; Hirotomo Shibaguchi; Hiromi Yamada; Masahide Kuroki; Shin'ichiro Yasunaga
Journal:  Cancer Cell Int       Date:  2019-11-15       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.